HB5969, the “Linking Abortion-drug Batches for Enforcement and Liability Act” or “LABEL Act,” would amend the Federal Food, Drug, and Cosmetic Act to require abortion-inducing drugs to bear a label identifying the name and address of the dispenser and the name of the prescriber. Under the bill, such drugs would be deemed misbranded unless they include that information on the label.
The bill also defines “abortion-inducing drug” broadly as a drug intended, alone or with other drugs, to end a pregnancy or kill an unborn child, but excludes drugs used to remove a dead unborn child or to treat an ectopic pregnancy. It includes a preemption-style provision barring states and local governments from enforcing labeling requirements for abortion-inducing drugs that are less stringent than the federal standard established by the bill, and it contains a severability clause.
Impact
If enacted, the bill would change federal drug-labeling law by adding a specific misbranding rule for abortion-inducing drugs and by requiring identifying information for the dispenser and prescriber. It would affect manufacturers, dispensers, prescribers, and regulators under the Federal Food, Drug, and Cosmetic Act, while also limiting state and local governments from adopting or enforcing weaker labeling rules for these drugs.
Sentiment
The bill appears to reflect strong support from its Republican sponsors for tighter regulation and traceability of abortion-inducing drugs. There is no recorded committee debate or vote history in the provided materials, so no bipartisan support or opposition is documented here. Based on the bill text alone, the measure is framed as an enforcement and liability tool rather than a broader abortion policy change.
Contention
The main point of contention is likely the bill’s treatment of abortion-inducing drugs as a distinct category subject to special labeling and enforcement rules, which supporters may view as improving accountability and opponents may view as an additional restriction on abortion access. The definition of abortion-inducing drug, the requirement to disclose the dispenser and prescriber, and the limitation on state labeling rules are all likely to be disputed, especially by abortion-rights advocates, healthcare providers, and states that regulate abortion-related medication differently.